Glaukos (GKOS) COO Gilliam sold 10,498 shares for $1.34M at an average $127.68 under a 10b5-1 plan
Insider transactions reported
Joseph E Gilliam (President & COO at Glaukos Corporation, GKOS) reported that they sold 10,498 shares for $1.34M at an average $127.68, and acquired 10,498 shares at $55.18 on Jan 22, 2026. After these transactions the filing shows 92,366 shares held directly.
- Reporting person
- Gilliam Joseph E
- Role
- PRESIDENT & COO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 22, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +10,498 | $55.18 | $579K | 102,864 direct |
| Jan 22, 2026 | Open-market sale (S) | Common Stock1, 2, 3, ... | -10,498 | avg $127.68 | $1.34M | 92,366 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 22, 2026 | Exercise or conversion of a derivative (M) | Stock Option (Right to Buy)On 10,498 Common Stock7, 8, 9 | -10,498 | avg $55.18 | $579K | 30,713 direct |
Holdings before and after
- Stock Option (Right to Buy): 62,411 to 30,713 direct
Footnotes from the filing
- 1. Includes 62,605 restricted stock units that have not yet vested or been delivered to the Reporting Person.
- 2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
- 3. This transaction was executed in multiple trades at prices ranging from $125.56 to $126.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 7. The option exercises reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
- 8. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
- 9. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Gilliam report in this GKOS Form 4?
Joseph E Gilliam (President & COO at Glaukos Corporation, GKOS) reported that they sold 10,498 shares for $1.34M at an average $127.68, and acquired 10,498 shares at $55.18 on Jan 22, 2026. After these transactions the filing shows 92,366 shares held directly.
How many GKOS shares does Gilliam hold after this filing?
The filing shows 92,366 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this GKOS insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for GKOS
Across the 7 sessions after earlier GKOS headlines, the stock closed higher 4 times and lower 3 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GKOS | SPY |
|---|---|---|---|
| Jan 20, 2026 | Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 | +2.7% | -2.0% |
| Jan 14, 2026 | Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance | -5.3% | -0.5% |
| Dec 16, 2025 | Glaukos Announces Participation in J.P. Morgan Healthcare Conference | +1.8% | -0.3% |
| Nov 3, 2025 | Glaukos Announces Participation in Upcoming Investor Conferences | -0.8% | +0.2% |
| Oct 30, 2025 | Glaukos Announces Third Quarter 2025 Financial Results | +13.9% | -1.1% |
| Oct 27, 2025 | Glaukos upgraded by Wells Fargo with a new price target | +1.4% | +1.2% |
Earlier insider filings at GKOS
- Jan 24, 2026PRESIDENT & COO Gilliam Joseph E exercised 4,502 shares at a strike of $55.18 and sold $561,174 worth of shares (4,502 units at $124.65) (SEC Form 4)
- Jan 20, 2026CHAIRMAN & CEO Burns Thomas William exercised 275,000 shares at a strike of $16.49 and sold $31,625,000 worth of shares (275,000 units at $115.00) (SEC Form 4)
- Jan 8, 2026Director Hoffmeister David F was granted 753 shares, increasing direct ownership by 2% to 32,671 units (SEC Form 4)
- Jan 8, 2026Director Wen Leana was granted 623 shares, increasing direct ownership by 3% to 21,439 units (SEC Form 4)
- Jan 8, 2026Director Weisner Aimee S was granted 623 shares, increasing direct ownership by 3% to 19,786 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2015
Follow GKOS and get a push notification the moment its next story breaks.